HER2-low and HER2-ultralow metastatic breast cancer and trastuzumab deruxtecan: Common clinical questions and answers

In a clinical review, researchers discussed the importance of HER2 testing and classification to help guide treatment decisions, especially in context of the emerging HER2-low and HER2-ultralow classifications and the data supporting the clinical activity of trastuzumab deruxtecan in these settings. They also examined adverse event management as well as the sequencing of treatments for these patient populations.